Cytoreductive procedures in the early management in cases of leukemia and hyperleukocytosis in children.
Cytoreduction for hyperleukocytosis before the initiation of primary therapy may reduce morbidity and mortality from blast cell lysis in children with acute lymphoblastic leukemia (ALL) and from leukostasis in children with acute nonlymphoblastic leukemia (ANLL) or chronic myelogenous leukemia (CML). The clinical features of 35 children (23 with ALL, 5 with ANLL, and 7 with CML) who underwent cytoreduction before the institution of definitive therapy were studied. Twelve children had exchange transfusions and 23 underwent leukaphereses. The cytoreductive procedures were equally effective in removing peripheral leukocytes (median decrease, 60%) and produced no complications. Ten children required additional cytoreduction because of further leukocyte increase before chemotherapy became effective. Three children with ALL who had renal insufficiency and metabolic derangement prior to leukapheresis subsequently required additional therapeutic measures. Three children with respiratory symptoms attributable to leukostasis improved after cytoreduction, and there were no episodes of intracerebral hemorrhage. These observations demonstrate the safety and efficiency of exchange transfusion and leukapheresis, and provide support for the role of cytoreduction in the early management of cases of hyperleukostasis and leukemia in children.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005078:Exchange Transfusion, Whole Blood; D005260:Female; D006801:Humans; D007937:Leukapheresis; D007938:Leukemia / Q000473:pathology / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D007964:Leukocytosis / Q000473:pathology / Q000628:therapy*; D008297:Male